


Clopimozide

Chemical Properties

CAS No. :	53179-12-7
Formula:	C ₂₈ H ₂₈ ClF ₂ N ₃ O
Molecular Weight:	495.99
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Clopimozide (R-29764) acts as a calcium channel antagonist and inhibits [3H] nilandipine binding. Clopimozide is a novel and orally available long-acting antischizophrenic psychostatic compound.
Targets(IC50)	Calcium Channel
In vivo	Clopimozide (5 and 35 mg) in 10 patients' plasma levels were determined with the radio-immunological method. The product exhibited a marked effect on schizophrenic target symptoms (significant at the 0.001 and 0.01 levels), of at least one week's duration, with an absence of sedation and a low degree of extrapyramidal side effects. Clopimozide appears to be particularly suitable for the neuroleptic long-term treatment of compensated schizophrenic patients with insight into their disease.[3]

Solubility Information

Solubility	DMSO: 4.96 mg/mL (10 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0162 mL	10.0808 mL	20.1617 mL
5 mM	0.4032 mL	2.0162 mL	4.0323 mL
10 mM	0.2016 mL	1.0081 mL	2.0162 mL
50 mM	0.0403 mL	0.2016 mL	0.4032 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

De Cuyper HJ, et al. Therapeutical significance of clopimozide in the treatment of chronic psychotic patients. Acta Psychiatr Scand. 1979;59(5):561-574.

Janssen PA, et al. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series. Arzneimittelforschung. 1975;25(8):1287-1294.

Floru L, et al. Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764). Arzneimittelforschung. 1978;28(2):341-344.

Knapen J, et al. Treatment of chronic psychoses with oral clopimozide. Acta Psychiatr Belg. 1976;76(4):644-657.

Gould RJ, et al. Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A. 1983;80(16):5122-512

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481